192 related articles for article (PubMed ID: 34448427)
41. Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients.
Palladini G; Milani P; Foli A; Vidus Rosin M; Basset M; Lavatelli F; Nuvolone M; Obici L; Perlini S; Merlini G
Leukemia; 2014 Dec; 28(12):2311-6. PubMed ID: 25059496
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients Presenting With Symptomatic Heart Failure.
Sperry BW; Ikram A; Hachamovitch R; Valent J; Vranian MN; Phelan D; Hanna M
J Am Coll Cardiol; 2016 Jun; 67(25):2941-8. PubMed ID: 27339491
[TBL] [Abstract][Full Text] [Related]
43. Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen.
Dumas B; Yameen H; Sarosiek S; Sloan JM; Sanchorawala V
Amyloid; 2020 Dec; 27(4):244-249. PubMed ID: 32551974
[TBL] [Abstract][Full Text] [Related]
44. Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial.
Huang X; Wang Q; Chen W; Zeng C; Chen Z; Gong D; Zhang H; Liu Z
BMC Med; 2014 Jan; 12():2. PubMed ID: 24386911
[TBL] [Abstract][Full Text] [Related]
45. [Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
Charliński G; Wiater E; Jedrzejczak WW
Pol Merkur Lekarski; 2012 Apr; 32(190):217-20. PubMed ID: 22708276
[TBL] [Abstract][Full Text] [Related]
46. Primary Systemic Amyloidosis: A Case Report.
Oli SS; Jha A; Karki A; Sapkota S; Adhikari L
JNMA J Nepal Med Assoc; 2023 Oct; 61(266):822-824. PubMed ID: 38289775
[TBL] [Abstract][Full Text] [Related]
47. Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial.
Shen KN; Fu WJ; Wu Y; Dong YJ; Huang ZX; Wei YQ; Li CR; Sun CY; Chen Y; Miao HL; Zhang YL; Cao XX; Zhou DB; Li J
Circulation; 2022 Jan; 145(1):8-17. PubMed ID: 34503349
[TBL] [Abstract][Full Text] [Related]
48. [Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens].
Adam Z; Stork M; Pour L; Krejčí M; Zahradová L; Sandecká V; Hájek R; Cermáková Z; Pospíšilová Y; Navrátil M; Král Z; Mayer J
Vnitr Lek; 2012 Dec; 58(12):896-903. PubMed ID: 23427947
[TBL] [Abstract][Full Text] [Related]
49. Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the Treatment of Newly Diagnosed AL Amyloidosis: Impact of Response on Survival Outcomes.
Diaz-Pallares C; Lee H; Luider J; Duggan P; Neri P; Tay J; MacCulloch S; Bahlis NJ; Jimenez-Zepeda VH
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):394-399. PubMed ID: 32146104
[TBL] [Abstract][Full Text] [Related]
50. Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis.
Le Bras F; Molinier-Frenkel V; Guellich A; Dupuis J; Belhadj K; Guendouz S; Ayad K; Colombat M; Benhaiem N; Tissot CM; Hulin A; Jaccard A; Damy T
Eur J Cancer; 2017 May; 76():183-187. PubMed ID: 28334621
[TBL] [Abstract][Full Text] [Related]
51. The efficacy and safety of bortezomib-based chemotherapy for immunoglobulin light chain amyloidosis: A systematic review and meta-analysis.
Liu B; Bai M; Wang Y; Wang D; Zhao J; Li L; Dong R; Sun S
Eur J Intern Med; 2019 Nov; 69():32-41. PubMed ID: 31447275
[TBL] [Abstract][Full Text] [Related]
52. Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy.
Manwani R; Mahmood S; Sachchithanantham S; Lachmann HJ; Gillmore JD; Yong K; Rabin N; Popat R; Kyriakou C; Worthington S; Sharpley F; Smith M; Shah R; Cheesman S; Hawkins PN; Wechalekar AD
Br J Haematol; 2019 Dec; 187(5):638-641. PubMed ID: 31388995
[TBL] [Abstract][Full Text] [Related]
53. Management of AL amyloidosis in 2020.
Palladini G; Milani P; Merlini G
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):363-371. PubMed ID: 33275753
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis.
Lamm W; Willenbacher W; Lang A; Zojer N; Müldür E; Ludwig H; Schauer-Stalzer B; Zielinski CC; Drach J
Ann Hematol; 2011 Feb; 90(2):201-6. PubMed ID: 20821326
[TBL] [Abstract][Full Text] [Related]
55. Bortezomib plus dexamethasone results in a late organ response in primary heavy-chain amyloidosis without a hematologic response.
Hassoun Y; Kharfan-Dabaja MA; Baz R
Hematol Oncol Stem Cell Ther; 2015 Sep; 8(3):138-9. PubMed ID: 25732670
[No Abstract] [Full Text] [Related]
56. Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment.
Gatt ME; Hardan I; Chubar E; Suriu C; Tadmor T; Shevetz O; Patachenco P; Dally N; Yeganeh S; Ballan-Haj M; Cohen Y; Trestman S; Muchtar E; Magen H; Jakubinsky J; Avivi I;
Eur J Haematol; 2016 Feb; 96(2):136-43. PubMed ID: 25827161
[TBL] [Abstract][Full Text] [Related]
57. Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up.
Basset M; Kimmich CR; Schreck N; Krzykalla J; Dittrich T; Veelken K; Goldschmidt H; Seckinger A; Hose D; Jauch A; Müller-Tidow C; Benner A; Hegenbart U; Schönland SO
Br J Haematol; 2021 Oct; 195(2):230-243. PubMed ID: 34341985
[TBL] [Abstract][Full Text] [Related]
58. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
Arnall JR; Usmani SZ; Adamu H; Mishkin J; Bhutani M
J Oncol Pharm Pract; 2019 Jun; 25(4):1021-1025. PubMed ID: 30477388
[TBL] [Abstract][Full Text] [Related]
59. Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.
Shah G; Kaul E; Fallo S; Cossor F; Smith H; Sprague K; Klein A; Miller K; Comenzo R
Clin Ther; 2013 Oct; 35(10):1614-20. PubMed ID: 24075726
[TBL] [Abstract][Full Text] [Related]
60. Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study.
Jain T; Kosiorek HE; Kung ST; Shah VS; Dueck AC; Gonzalez-Calle V; Luft S; Reeder CB; Adams R; Noel P; Larsen JT; Mikhael J; Bergsagel L; Stewart AK; Fonseca R
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):486-492.e1. PubMed ID: 29753692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
